Special Surgical Situations and Diabetes Management: Part 1

  • Sanjeev Kelkar
  • Shubhangi Muley
  • Prakash Ambardekar


It is desirable to admit patients who are not controlled optimally with or without being treated by insulin. Admissions 2–3 days prior to stabilize glucose control and optimize insulin doses will help postoperatively a great deal. The attempt should be to reach a fasting blood glucose level between 80 and 120 mg/dL and a bed time level of 100–140 m/dL. It is desirable to switch the patients on long-acting insulin to intermediate-acting insulin as it provides greater flexibility to alter doses for quicker control. Changing to intermediate acting insulin should be done preferably on admission for control or at least a couple of days earlier 1–2 days before elective surgery. In cardiac surgery in particular wide swings of glycemia occur. Hence frequent perioperative blood glucose monitoring followed by action by changing insulin infusion rates or subcutaneous doses or glucose supplementation as the case may be is crucial for better postoperative outcomes.


  1. 1.
    Niles NW, McGrath PD, Malenka D, et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol. 2001;37:1008–15.CrossRefGoogle Scholar
  2. 2.
    Investigators TBARI. Influence of diabetes on 5-year morbidity and mortality in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation. 1997;96:1761–9.CrossRefGoogle Scholar
  3. 3.
    Crock PA, Ley CJ, Martin IK, Alford FP, Best JD. Hormonal and metabolic changes during hypothermic coronary artery bypass surgery in diabetic and non-diabetic subjects. Diabet Med. 1988;5:47–52.CrossRefGoogle Scholar
  4. 4.
    Devineni R, Mckinzie FN. Surgery for coronary artery disease in patients with diabetes mellitus. Can J Surg. 1985;28:367–70, cited by Subhankar Chowdhury, Sujoy Ghosh SUPPLEMENT OF JAPI JULY 2007 VOL. 55.PubMedGoogle Scholar
  5. 5.
    Burton D, Nicholson G, Hall G. Endocrine and metabolic response to surgery. Cont Educ Anaesth Crit Care Pain. 2004;4(5):144–7. Scholar
  6. 6.
    Hirsch IB, McGill JB. Role of insulin management of surgical patients with diabetes mellitus. Diabetes Care. 1990;13:980.CrossRefGoogle Scholar
  7. 7.
    Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74–9.CrossRefGoogle Scholar
  8. 8.
    Desborough JP. The stress response to surgery. Br J Anaesth. 2000;85:109–17.CrossRefGoogle Scholar
  9. 9.
    Wright PD, Johnston IDA. The effect of surgical operation on growth hormone levels in plasma. Surgery. 1975;77(4):479–86.PubMedGoogle Scholar
  10. 10.
    Alberti KG, Marshall SM. Diabetes and surgery. In: Alberti KG, Krall LP, editors. Diabetes annual/4. New York, NY: Elsevier; 1988. p. 248–71.Google Scholar
  11. 11.
    Clutter WE, Rizza RA, Gerich JE, Cryper PE. Regulation of glucose metabolism by sympathochromaffin catecholamines. Diabetes Metab Rev. 1988;4:17–30.CrossRefGoogle Scholar
  12. 12.
    Schricker T, Carvalho G. An ounce of prevention worth a pound of cure. Can J Anesth. 2004;51:948–9.CrossRefGoogle Scholar
  13. 13.
    McAlister FA, Man J, Bistritz L, et al. Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care. 2003;26:1518–24.CrossRefGoogle Scholar
  14. 14.
    Simmons D, Morton K, Laughton S, Scott DJ. A comparison of two intravenous insulin regimens among surgical patients with insulin dependent diabetes mellitus. Diabetes Educ. 1994;20:422–7.CrossRefGoogle Scholar
  15. 15.
    Bolk J, van der Ploeg T, Cornel JH, et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001;79:207–14.CrossRefGoogle Scholar
  16. 16.
    Lawrie GM, Morris GC, Glaeser DH. Influence of diabetes mellitus on the results of coronary artery bypass surgery. JAMA. 1986;256:1967–71.CrossRefGoogle Scholar
  17. 17.
    Halkos ME, Lattouf OM, Puskas JD, et al. Elevated preoperative hemoglobin A1c level is associated with reduced long-term survival after coronary artery bypass surgery. Ann Thorac Surg. 2008;86:1431–7.CrossRefGoogle Scholar
  18. 18.
    Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after non cardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996;335:1713–20.CrossRefGoogle Scholar
  19. 19.
    McAlister FA, Amad H, Man J, Tandon P, Bistriz L. Diabetes and coronary bypass surgery. Diabetes Care. 2003;26:1518–24.CrossRefGoogle Scholar
  20. 20.
    Furnary A, Gao G, Grunkeimer GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003;125:1007–21.CrossRefGoogle Scholar
  21. 21.
    Rady MY, Ryan T, Starr NJ. Perioperative determinants of morbidity and mortality in elderly patients undergoing cardiac surgery. Crit Care Med. 1998;26:225–35.CrossRefGoogle Scholar
  22. 22.
    Haga KK, McClymont KL, Clarke S, et al. The effect of tight glycemic control, during and after cardiac surgery, on patient mortality and morbidity: a systematic review and meta analysis. J Cardiothorac Surg. 2011;6(1):Article 3.CrossRefGoogle Scholar
  23. 23.
    Carvalho G, Moore A, Qizilbash B, et al. Maintenance of normoglycemia during open cardiac surgery. Anesth Analg. 2004;99:319–24.CrossRefGoogle Scholar
  24. 24.
    Parsonage WA, Hetmanski D, Cowley AJ. Beneficial haemodynamic effects of insulin in chronic heart failure. Heart. 2001;85:508–13.CrossRefGoogle Scholar
  25. 25.
    Pomposelli J, Baxter J, Babineau T, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. J Parent Enter Nutr. 1998;22:77–81.CrossRefGoogle Scholar
  26. 26.
    Measley RE Jr. Chapter 3: Antimicrobial prophylaxis: prevention of postoperative infections. In: Merli GJ, Weitz HH, editors. Medical management of the surgical patient. 3rd ed. Philadelphia, PA: Saunders; 2008, eBook ISBN: 9781437710588, Paperback ISBN: 9781416023852.Google Scholar
  27. 27.
    Duncan AI, Koch CG, Xu M, et al. Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery. Anesth Analg. 2007;104:42–50.CrossRefGoogle Scholar
  28. 28.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRefGoogle Scholar
  29. 29.
    Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 2012;40:3251–76.CrossRefGoogle Scholar
  30. 30.
    Ali Z, Prabhakar H. Fluid Management during Neurosurgical Procedures. J Neuroanaesthesiol Crit Care. 2016;3(Suppl S1):35–40.Google Scholar
  31. 31.
    Glister BC, Vigersky RA. Perioperative management of type 1 diabetes mellitus. Endocrinol Metab Clin N Am. 2003;32:411–36.CrossRefGoogle Scholar
  32. 32.
    Greenstone MA, Shaw AB. Alternate day corticosteroid causes alternate day hyperglycaemia. Postgrad Med J. 1987;63:761–4.CrossRefGoogle Scholar
  33. 33.
    Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in type 1 Diabetes. Diabetes Care. 2000;23:639–43.CrossRefGoogle Scholar
  34. 34.
    Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5:673–82.CrossRefGoogle Scholar
  35. 35.
    American Association of Clinical Endocrinologists, AACE Diabetes Resource Center. Management of common comorbidities of diabetes. Jacksonville, FL: American Association of Clinical Endocrinologists, AACE Diabetes Resource Center; 2016. Accessed June 2016.Google Scholar
  36. 36.
    Kroon L. Making sense of medications for diabetes [lecture]. San Francisco, CA: University of California, San Francisco, Osher Center for Integrative Medicine; n.d.Google Scholar
  37. 37.
    Lum CT, Sutherland DER, Goetz FC, et al. Management of the diabetic patient before, during and after surgery with special emphasis on uremic patients and kidney transplant recipients. Minn Med. 1985;68:693–6.PubMedGoogle Scholar
  38. 38.
    Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19:1411–8.CrossRefGoogle Scholar
  39. 39.
    Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95(5):647–52.CrossRefGoogle Scholar
  40. 40.
    Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet beta-cell survival. J Biol Chem. 2010;285:40050–9.CrossRefGoogle Scholar
  41. 41.
    Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today. 2007;12:112–24.CrossRefGoogle Scholar
  42. 42.
    Yang SB, Lee HY, Young DM, et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med (Berl). 2012;90:575–85.CrossRefGoogle Scholar
  43. 43.
    Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med. 2001;344:726–31. Scholar
  44. 44.
    Becker BN, Rush SH, Dykstra DM, Becker YT, Port FK. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med. 2006;166:44–8. Scholar
  45. 45.
    Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62:1440–6.CrossRefGoogle Scholar
  46. 46.
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–85.CrossRefGoogle Scholar
  47. 47.
    Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3:590–8.CrossRefGoogle Scholar
  48. 48.
    Fourtounas C. World J Transplant. 2014;4(2):102–10.CrossRefGoogle Scholar
  49. 49.
    Arnouts P, Bolignano D, Nistor I, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant. 2014;29(7):1284–300.CrossRefGoogle Scholar
  50. 50.
    Suresh KR. Statistics from a tertiary Institute of Vascular Surgery, JIVAS, Bengaluru, India. Bengaluru: JIVAS; 2018.Google Scholar
  51. 51.
    Crawford F1, Welch K, Andras A, Chappell FM. Ankle brachial index for the diagnosis of lower limb peripheral arterial disease. Cochrane Database Syst Rev. 2016;9:CD010680.PubMedGoogle Scholar
  52. 52.
    Arsenault KA, McDonald J, Devereaux PJ, Thorlund K, Tittley JG, Whitlock RP. The use of transcutaneous oximetry to predict complications of chronic wound healing: a systematic review and meta-analysis. Wound Repair Regen. 2011 Nov;19(6):657–63.CrossRefGoogle Scholar

Additional Reading

  1. National Guidelines for Management of Diabetic Foot, published by Diabetic Foot society of India, 2017.Google Scholar
  2. Preoperative Testing and Medication Management The Ohio State University Wexner Medical Center. 2017.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Sanjeev Kelkar
    • 1
  • Shubhangi Muley
    • 2
  • Prakash Ambardekar
    • 3
  1. 1.Private PracticePuneIndia
  2. 2.Senior Consultant AnesthesiologistCentral India Institute of Medical ScienceNagpurIndia
  3. 3.Consultant, AnesthesioligistFortis S L Raheja HospitalMumbaiIndia

Personalised recommendations